NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market on Wednesday that its revenues in the second quarter jumped 91 percent year over year, but missed the consensus Wall Street estimate as changes in molecular diagnostic billing and payment codes delayed receipt of payments.

For the three months ended June 30, the San Diego-based company pulled in $34.9 million in total revenues, compared to $18.3 million a year ago, but was well short of the consensus analyst estimate of $46.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.